The FDA advisory panel recommended approval of Regeneron’s VEGF Trap-Eye for wet AMD. The fusion protein is likely to become a serious challenger to Genentech’s Lucentis and off-label IVT Avastin.
Premium IOL procedures approached 15 percent of all US IOL procedures during Q1-2011.
In Q1-2011, refractive surgeries showed rather anemic improvement, as the consumer confidence index again dipped during this protracted recession.
Is LASIK yesterday’s technology or is it poised for recovery? Both arguments raise valid issues.
Our new 2011 Comprehensive Report on the Global Cataract Equipment Market forecasts the five-year impact of laser refractive cataract surgery in wealthier nations and the conversion to ultrasonic phaco in emerging markets.
This month's news includes the latest from CROMA, Bausch & Lomb, Merge Healthcare, Ophthalmic Imaging Systems, Alcon, NovaBay Pharmaceuticals, Pfizer and pSivida.
You are not currently logged in.
©2017 Market Scope
Lost your Password